A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease

Status:
Completed

Trial end date:
2006-10-01

Target enrollment:

Participant gender:

The purpose of this study is to examine the safety and efficacy of CNTO 1275 in participants with active Crohn's Disease.

Phase 2

Centocor, Inc.

Ustekinumab